MedPath
TGA Approval

OPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vial (372783)

372783

OPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vial

Bristol-Myers Squibb Australia Pty Ltd

October 7, 2022

Medicine

Medicine

Active

Registered

Product Information

Consumer Medicine Information

https://medical-cdn.nocode.com/drug_tga/fe1407221175da9e20cfb1b894853108.pdf

Product Information

https://medical-cdn.nocode.com/drug_tga/3ba313c10e543f13649f37cd26288a67.pdf

Active Ingredients

nivolumab

relatlimab

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

OPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vial (372783) - TGA 批准文号 | MedPath